Pcas: net sales as of June 30, 2020
23 Juillet 2020 - 6:00PM
Pcas: net sales as of June 30, 2020
Ecully, July 23, 2020
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as of June 30, 2020.
The PCAS Group has generated consolidated net
sales of €105.1 million as of June 30, 2020, representing an
increase of 2.8% compared to the same period in the previous
financial year (+2.2% at a constant exchange rate).
In millions of euros |
|
2020 |
|
2019 |
|
% change |
|
2020 At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
Sales as
of 30 June |
|
105.1 |
|
102.3 |
|
2.8% |
|
104.5 |
|
2.2% |
Pharmaceutical Synthesis |
|
72.7 |
|
62.5 |
|
16.4% |
|
72.1 |
|
15.5% |
Fine Specialty Chemicals |
|
32.4 |
|
39.8 |
|
-18.5% |
|
32.4 |
|
-18.6% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business in Health
generated sales of €72.7 million, up 16.4% compared to 2019 (+15.5%
at constant exchange rate). The first semester of 2019 had been
affected by operational difficulties at one of our sites and
shortages in raw material supplies. The first half of 2020 confirms
the gradual return to normal operations of our industrial assets.
During that period, PCAS has deployed intensive efforts to respond
to the public health emergency with regard to CoVid-19, allocating
some of its production and R&D capacities to (i) the
development of antiviral products and (ii) the production of
hydro-alcoholic solution.
Fine Specialty Chemicals
Net sales of fine specialty chemicals amounted
to €32.4 million, down 18.5% compared to 2019 (-18.6% at constant
exchange rate). During the first half of the year, the Electronics
business was stable but the Lubricants and Fine Chemicals
activities have suffered a sharp decrease in demand, Lubricants in
particular, as their respective end markets (automotive and
construction) were hit very hardly by the CoVid-19crisis.
Outlook
As mentioned in our press release on March 31,
2020, the global crisis relating to the CoVid-19 is changing
everyday and there are still uncertainties regarding its duration,
extent and effects on companies' production lines and consumption
in general.
To date, the PCAS Group has not seen any major
impacts on its business activities and earnings. However, it is
hard to anticipate the potential impacts in the medium term. This
crisis calls for cautiousness, and due to these exceptional
circumstances, the Group has suspended its financial targets and
its strategic business objectives until the situation becomes
clearer.
NEXT FINANCIAL DISCLOSURE:
2020 first half results, September 8, 2020
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €200.9 million in 2019 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
Newcap |
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor |
Tél. : +33 1 69 79 60 00www.pcas.com |
Tél. : +33 1 44 71 98 53pcas@newcap.eu |
- PR_PCAS_Chiffre d'Affaires 30 juin 2020
PCAS (EU:PCA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
PCAS (EU:PCA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024